Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

Muscular dystrophy can appear in infancy up to middle age or later, and its form and severity are determined in part by the age at which it occurs. Some types of muscular dystrophy typically ...

Wasting of muscle tissue can also occur with malnutrition and various nerve or muscle-related health conditions such as ...

Medcare’s approach goes beyond clinical excellence. Patients benefit from a multidisciplinary team that includes experts in ...

The test stimulation of the spinal cord was successful in 24 patients; the other 12 patients did not receive implanted stimulators. In an intention-to-treat analysis, the group assigned to receive ...

These data demonstrate the breadth of Roche’s neuromuscular portfolio across spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). “These longer-term results are encouraging for people ...

The Muscular Dystrophy Association operates care centers across the country, linking patients with teams of specialists who work frequently with neuromuscular diseases. The words “spinal ...

Newly approved SMA therapies show promise but face global accessibility challenges, widening healthcare disparities due to high costs and limited availability. Newborn screening for SMA is ...

Spinal muscular atrophy (SMA) is a genetic disease that affects the nervous system and, mostly, the muscles it controls. It weakens muscles and can lead to problems breathing, eating, and walking.

Steiner added, “For patients with spinal muscular atrophy specifically ... study of patients with SMA or Duchenne and Becker muscular dystrophy. Another similar finding between the studies ...

San Diego-based Kate is focused on preclinical programs aimed at Duchenne muscular dystrophy (DMD), facioscapulohumeral ... the gene therapy Zolgensma for spinal muscular atrophy—has been ...